RoboSense LiDAR Partners with Banma and AutoX on High-Level Autonomous Driving Platform
RoboSense (https://www.robosense.ai/), the leading smart LiDAR sensor provider announced a strategic partnership with Banma Network Technology, an intelligent automobile operating system and solution provider that cooperated with Alibaba Group and SAIC Motor, and AutoX, China's most advanced self-driving AI platform, to build a high-level autonomous driving platform for intelligent vehicles through in-depth cooperation in the 3D LiDAR sensor, AI algorithm, and intelligent automobile operating system, and create an advanced smart cockpit based on human-machine co-driving.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005523/en/
(Photo: Business Wire)
The cooperation will promote the integration of smart cockpits with autonomous driving systems through the fusion of hardware, software, and AI capabilities. RoboSense will provide the robust LiDAR sensor solution that not only meets the need for high-level autonomous driving systems, but also for Banma's advanced intelligent cockpit systems. RoboSense LiDAR provides accurate environmental perception data for the AutoX autonomous driving system "AI driver", and empowers the safety of Banma's intelligent automobile operating system.
In January 2021, RoboSense and Banma jointly established the Intelligent Perception Innovation Center. Three months later, the two parties formed a mass-production-ready solution based on the intelligent automobile operating system and automotive-grade solid-state RS-LiDAR-M1, which meets the requirements of both autonomous passenger cars and the RoboTaxi.
The Executive President and Co-Founder of RoboSense, Mark Qiu said, " With three parties' efforts on the integration of intelligent cockpit system, perception system, and AI autonomous driving solution, we are able to provide a new generation of intelligent vehicle solutions with more potential values to OEMs and other customers."
The CIO of Banma, Qiang Xu said, " Intelligent interaction, intelligent service, and intelligent driving are the three basic aspects of smart driving cars. At present, smart cockpits and autonomous driving are gradually merging with each other. In terms of hardware, we provide RoboSense with system-level support to ensure its perception power is fully utilized. As for the algorithm, we provide AutoX with a rich toolchain, cloud and end service system to create a sustainable and efficient ecological collaboration system. "
The Founder and CEO of AutoX, Jianxiong Xiao said, "With the fully driverless RoboTaxi is becoming a reality in China, passengers will have more free time in the car. More intelligent services and interactions with the car are needed for a smart and enjoyable travel experience. A complete product ecosystem formed by three parties will create a safe and enjoyable autonomous driving solution. "
About RoboSense
RoboSense is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to possess outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability more superior to humans. https://www.robosense.ai/
About Banma
Banma provides an intelligent automobile operating system, intelligent automobile solutions as well as digital transportation solutions for both automotive and transportation industries. Powered by self-developed AliOS, Banma Automobile Solutions currently have collaborated with more than 1 million vehicles. In the future, Banma will promote transportation digitalization by providing man-machine co-driving and vehicle-road collaboration. https://www.ebanma.com
About AutoX
AutoX is the market leader for RoboTaxi in China. AutoX is the only company operating fully driverless RoboTaxi fleet on public roads in China without safety drivers. The company’s self-driving platform is capable of handling the densest and most dynamic traffic conditions in urban cities around the world. AutoX is the world's second permit holder for California DMV’s completely driverless RoboTaxi permit. https://www.autox.ai
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005523/en/
Contact information
Cassie Gong, RoboSense PR
sqgong@robosense.ai
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom